Compare Pelat Timah Nusantara Tbk. (NIKL) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pelat Timah Nusantara Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Pelat Timah Nusantara Tbk. trades at Rp224 (market cap 595.51B, 9.73M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Pelat Timah Nusantara Tbk. is far larger — about 5.7× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| NIKL | SCPI | |
|---|---|---|
Market Cap | 595.51B | 104.4B |
Volume | 9.73M | — |
Lot | 97.35K | — |
Turnover | 2.21B | — |
Average Price | 227.38 | — |
Value | 2.21B | — |
Indicative Equilibrium Price | 224 | — |
Indicative Equilibrium Volume | 2.27K | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pelat Timah Nusantara Tbk.
PT Pelat Timah Nusantara Tbk (PT Latinusa) was the first company in Indonesia that produces high-quality tinplate with international standards. PT Latinusa was founded on August 19, 1982 under the Company Act No.45, drawn up before Imas Fatimah, SH, and the current majority shareholder is the Japanese consortium consisting of Nippon Steel Corporation, Mitsui Co.. Ltd.., Nippon Steel Trading Co.., And Metal One. Nippon Steel Corporation is also the provider of our main raw material, Tin Mill Black Plate (TMBP), so the availability of raw materials is always guaranteed.
Read more on NIKL →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
